504
Participants
Start Date
June 10, 2025
Primary Completion Date
March 31, 2028
Study Completion Date
November 30, 2029
BNT323/DB-1303
intravenous (IV) infusion
Doxorubicin
IV bolus or infusion
Paclitaxel
IV infusion
RECRUITING
Taipei Veterans General Hospital, Taipei
RECRUITING
China Medical University Hospital, Taichung
RECRUITING
National Cheng Kung University Hospital, Tainan City
RECRUITING
Taichung Veterans General Hospital, Taichung
RECRUITING
Gosford Hospital, Gosford
NOT_YET_RECRUITING
Wollongong Hospital, Wollongong
RECRUITING
Sunshine Hospital, Saint Albans
RECRUITING
Mater Hospital Brisbane, South Brisbane
RECRUITING
MacKay Memorial Hospital_ Taipei Branch, Taipei
RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
RECRUITING
The Affiliated Hospital of Nanjing University Medical School, Nanjing
RECRUITING
Tianjin Medical University Cancer Institute & Hospital, Tianjin
RECRUITING
Jiangxi Maternal and Child Health Hospital, Nanchang
RECRUITING
The Second Affiliated Hospital of Chongqing Medical University, Chongqing
RECRUITING
Hubei Cancer Hospital, Wuhan
RECRUITING
Xiangyang Central Hospital, Xiangyang
RECRUITING
The Second Affiliated Hospital of Zhengzhou University, Zhengzhou
RECRUITING
Cancer Hospital of Shantou University Medical College, Shantou
RECRUITING
Guangxi Medical University Affiliated Tumor Hospital, Nanning
RECRUITING
Sichuan Provincial People's Hospital, Chengdu
RECRUITING
The First Affiliated Hospital of Xian Jiaotong University, Xi'an
RECRUITING
Gansu Provincial Maternity and Child-care Hospital, Lanzhou
RECRUITING
Health Sciences Centre, St. John's
RECRUITING
Gangnam Severance Hospital, Yonsei University Health System, Seoul
RECRUITING
Castle Hill Hospital, Cottingham
RECRUITING
Royal Cornwall Hospital, Truro
Lead Sponsor
DualityBio Inc.
INDUSTRY
BioNTech SE
INDUSTRY